



Reg. Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai - 400053
Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com
CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

November 18, 2019

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

With respect to our outcome uploaded on November 14, 2019 regarding Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2019 and Limited Review Report thereon, we had inadvertently not uploaded Cash Flow Statement for the half year ended September 30, 2019 in the note thereto. The same is attached herewith.

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**

A handwritten signature in blue ink, appearing to read "Abha Kapoor", with a horizontal line underneath.

Abha Kapoor
Director (Finance) and CFO
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2019

	Particulars	30-Sep-19	31-Mar-19
		RUPEES	RUPEES
A	<u>Cash Flow From Operating Activities</u>		
	Net Profit before tax and Extraordinary Items	(193,195)	(1,824,582)
	Adjustment for :		
	Depreciation	9,249	3,630
	Operating Profit before working Capital Changes	(183,946)	(1,820,952)
	Adjustment for Capital Changes:		
	Increase/Decrease in Payables & Provisions	68,240	26,605
	Cash Generated From Operations	(283,777)	(1,962,418)
	Income Tax / Deferred Tax Paid	-	-
	Extraordinary items	-	(1,710,556)
	<u>Net cash from Operating Activities</u>	(283,777)	(251,862)
B	<u>Net Cash From Investing Activities</u>	-	-
	Increase/Decrease in Fixed Assets	(168,071)	(168,071)
	Increase/Decrease in Capital WIP	(1,401,358)	-
	<u>Net Cash From Investing Activities</u>	(1,569,429)	(168,071)
C	<u>Cash Flow From Financing Activities</u>		
	Increase/Decrease in Trade Payables	(561,555)	(1,062,629)
	Increase/Decrease in Cash Loans and advances	(296,000)	(1,145,000)
	Increase/Decrease in Trade Receivables	2,350,000	497,202
	<u>Net Cash From Financing Activities</u>	1,492,445	(1,710,427)
	Net Increase (Decrease) in cash & cash equivalents (A+B+C)	(360,761)	(1,962,289)
	Opening Balance of Cash & Cash Equivalents	1,400,334	3,362,623
	Closing Balance of Cash & Cash Equivalents	1,039,573	1,400,334

Place **Mumbai**
Date **14-Nov-19**

For Rubra Medicaments Limited

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429